Whisper App User Engagement Jumps 140% with TigerText’s In-App Messaging Anonymous Confession App, Whisper Increases User Engagement and Improves Retention by 50% after Integrating TigerText’s Secure Messaging API, TigerConnect SANTA MONICA, CA (September 6, 2013) –...
Chimerix Initiates Phase 3 SUPPRESS Trial of Brincidofovir (CMX001) for Prevention of CMV in HCT Recipients DURHAM, N.C., Sept. 9, 2013 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of...
New Leaf Venture Partners Affirms Its Support of Roumell Asset Management’s Letter to Transcept Pharmaceuticals’ Board New York, NY September 9, 2013 – New Leaf Venture Partners (NLV Partners) announced that the Company has submitted today a letter to the Board...
Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 – Study Showed AF-219 Reduced Daytime Cough Frequency by 75% in Patients with Treatment-Refractory Chronic Cough – New Findings Featured in...
First Patient Enrolls in U.S. Salus Trial Evaluating Direct Flow Medical® Transcatheter Aortic Heart Valve System SANTA ROSA, Calif., September 10, 2013 – Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes,...
Durata Therapeutics Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) — Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER...
Recent Comments